Thelansis

Treatment-Resistant Depression (TRD) Emerging Therapy and TPP Insights Thelansis’s “Treatment-Resistant Depression (TRD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Treatment-Resistant Depression (TRD) Overview Treatment-Resistant Depression (TRD) is a challenging subtype of major depressive disorder in which patients fail to respond adequately to at least two different antidepressants given at proper doses and durations, often leaving them with persistent symptoms such as low mood, fatigue, sleep disturbances, and cognitive impairment. The condition affects nearly a third of individuals with depression and may be influenced by genetic factors, comorbid psychiatric or medical conditions, and poor medicati...

Charcot-Marie-Tooth (CMT) Market Outlook Thelansis’s “Charcot-Marie-Tooth (CMT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth (CMT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Charcot-Marie-Tooth (CMT) Overview Charcot-Marie-Tooth disease (CMT) encompasses a group of inherited disorders affecting the peripheral nerves, resulting in the progressive degeneration of both motor and sensory fibers, typically manifesting in childhood or adolescence with symptoms like muscle weakness, foot deformities, difficulty walking, and sensory loss. This condition is marked by significant genetic complexity; the most c...

Acute Kidney Injury (AKI) Market Outlook Thelansis’s “Acute Kidney Injury (AKI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Kidney Injury (AKI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acute Kidney Injury (AKI) Overview Acute Kidney Injury (AKI) is a sudden decline in kidney function, determined by elevated serum creatinine levels (indicating impaired kidney excretion) and reduced urine output (oliguria) within a 7-day timeframe. When AKI persists for over 3 months, it is termed Chronic Kidney Disease (CKD). It’s noteworthy that AKI and CKD frequently coexist in patients with preexisting CKD. Acute Renal Failur...

Cushing’s Syndrome (CS) Market Outlook Thelansis’s “Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Cushing’s Syndrome (CS) Overview Cushing’s Disease (CD), the leading cause of endogenous Cushing’s Syndrome (CS), results from the persistent overproduction of ACTH by a pituitary corticotroph adenoma. CD predominantly affects females, with a female-to-male ratio of 4-5:1, except in prepubertal patients, where males are more commonly affected. The peak age of onset occurs between 25 and 40 years. CD symptoms include typical CS features...

Epidermolysis Bullosa (EB) Market Outlook Thelansis’s “Epidermolysis Bullosa (EB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epidermolysis Bullosa (EB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Epidermolysis Bullosa (EB) Overview Epidermolysis bullosa is an infrequent, often severe genetic disorder characterized by skin, mucosal, or organ fragility, resulting in blistering or erosions, even from minor injuries. Severe forms of the condition can lead to skin issues like blistering, open wounds, and scarring and affect other body systems, such as the gastrointestinal, cardiovascular, genitourinary, ocular, and oral sys...

Familial Amyloid Polyneuropathy (FAP) Market Outlook Thelansis’s “Familial Amyloid Polyneuropathy (FAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Amyloid Polyneuropathy (FAP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Familial Amyloid Polyneuropathy (FAP) Overview Familial amyloid polyneuropathy (FAP) is a neurodegenerative condition characterized by the abnormal accumulation of mutant transthyretin (TTR) amyloid fibrils outside of cells, primarily in the peripheral nervous system. Mutations in the TTR gene lead to the destabilization of the TTR protein, causing it to change from its normal tetrameric form i...